Table 2.
Patients With an Unfavorable Change Beyond Minimal Clinical Important Difference in Global Health Status at the 12-Month Follow-up Compared to All Other Patients (N = 51)
| Variable | Unfavorable Change Beyond MCID in Global Health Status at 12-Month Follow-up (N = 12) |
All Other Patients (N = 39) |
P-value |
|---|---|---|---|
| Age at surgery, mean (SD) | 48.1 (9.8) | 41.5 (12.2) | .07 |
| Female, No (%) | 5 (41.7) | 21 (53.8) | .52 |
| KPS < 80 at admission, No (%) | 1 (8.3) | 5 (12.8) | 1.0 |
| Incidental, No (%) | 2 (16.7) | 6 (15.4) | 1.0 |
| History of seizures at admission, No (%) | 8 (66.7) | 26 (66.7) | 1.0 |
| Any neurological deficit at admission, No (%) | 5 (41.7) | 10 (25.6) | .30 |
| History of seizures at admission without any neurological deficit, No (%) | 5 (41.7) | 20 (51.3) | .74 |
| Tumor location, No (%) | |||
| Mainly frontal | 7 (58.3) | 22 (56.4) | 1.0 |
| Mainly temporal | 1 (8.3) | 8 (20.5) | .67 |
| Other | 4 (33.3) | 9 (23.1) | .47 |
| Tumor laterality, mainly left hemisphere, No (%) | 3 (25.0) | 20 (51.3) | .18 |
| Choice of neurosurgical intervention, No (%) | |||
| Tumor resection | 12 (100) | 36 (92.3) | 1.0 |
| Tumor type, oligodendroglioma, No (%) | 8 (66.7) | 18 (46.2) | .32 |
| Tumor grade, grade 2, No (%) | 8 (66.7) | 25 (64.1) | 1.0 |
| Treatment before 12-month follow-up | |||
| Start chemotherapy (delta T in months), mean (SD) | 4.5 (2.1) | 4.4 (2.4) | .93 |
| Start radiotherapy (delta T in months), mean (SD) | 3.8 (2.4) | 3.4 (2.6) | .68 |
| None, No (%) | 3 (25.0) | 5 (12.8) | .37 |
| Chemotherapy onlya, No (%) | 0 (0) | 5 (12.8) | .32 |
| Radiochemotherapya,b, No (%) | 9 (75.0) | 29 (74.4) | 1.0 |
| Other treatment details | |||
| Choice of chemotherapy first line drugs, temozolomide, No/N (%) | 4/9 (44.4) | 21/34 (61.8) | .46 |
| Radiation type, proton, No/N (%) | 7/9 (77.8) | 25/29 (86.2) | .61 |
| Radiation mean dose to the brain, GyRBEc, mean (SD) | 14.4 (5.0) | 14.1 (5.0) | .85 |
| Other relevant treatments and interventions, No/N (%) | |||
| Antiepileptic drug use at 12-month follow-up* | 10/11 (90.9) | 23/35 (65.7) | .14 |
| Physical rehabilitation* | 4/11 (36.4) | 5/39 (12.8) | .09 |
| Any permanent, new or worsened, neurological deficit, No (%) | 5 (41.7) | 7 (17.9) | .12 |
aEither temozolomide, lomustine, or procarbazine hydrochloride, lomustine and vincristine (PCV).
bEither concomitant or adjuvant.
cBiologic equivalent dose with fractions of 2Gy (α/β3).
*Observe missing data.